- ￥173 - 1264
- TargetMol
- T0078
- 2026年07月07日
2 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
231277-92-2
- 规格：
1mLx10mM(inDMSO)/10mg/25mg/50mg/100mg/200mg/500mg
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥210.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥173.0 |
| 规格： | 25mg | 产品价格： | ￥270.0 |
| 规格： | 50mg | 产品价格： | ￥362.0 |
| 规格： | 100mg | 产品价格： | ￥524.0 |
| 规格： | 200mg | 产品价格： | ￥766.0 |
| 规格： | 500mg | 产品价格： | ￥1264.0 |
Product Introduction
Bioactivity
| 名称 | Lapatinib |
| 描述 | Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression. |
| 细胞实验 | Cells are plated in 96-well plates, in the media, at the following densities: HFF and HN5, 1000 cells/well and BT474, 5000 cells/well. After 24 h, the cells are exposed to vehicle (0.3% DMSO) or Lapatinib (1 nM, 10 nM, 100 nM, 1μM, 10μM, and 100μM). Lapatinib is removed from the cells after 72 h and is replaced by either DMEM containing 10% FBS and 50 μg/mL Gentamicin (HFF and HN5) or RPMI containing 10% FBS and 50 μg/mL Gentamicin (BT474). Methylene blue staining is performed at the time points over a total period of 16 days. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide [1]. |
| 激酶实验 | The IC50 values for inhibition of enzyme activity are generated by measuring the inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves [1]. |
| 动物实验 | CD-1 nude female mice are used for HN5 human tumor xenografts, which are initiated by injection of a cell suspension in PBS: Matrigel (1:1). C.B-17 SCID female mice are used for BT474 human tumor xenografts, which are initiated by implantation of tumor fragments (20-100 mg) from established tumors. Tumor cells and fragments are implanted by s.c. injection in the right flank. The s.c. tumors are measured with calipers, and mice are weighed twice weekly. Tumor weight is estimated from tumor volume using this formula: length×width2/2=tumor volume (mm3). Treatment begins when tumors are palpable, 3-5 mm in diameter. Lapatinib (30 and 100 mg/kg) is administered p.o. twice daily for 21 days in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10) [1]. |
| 体外活性 | 方法：14 株人胃癌和食管癌细胞系用 Lapatinib (0.3125-10 µmol/L) 处理 6 天，使用 particle counter 检测细胞数。 结果：N87、OE19、NUGC4、NUGC3、FU97、SNU16 细胞对 Lapatinib 敏感，IC50 分别为 0.01、0.09、0.35、2.24、4.86、8.58 μmol/L。[1] 方法：人乳腺癌细胞 MDA-MB-231 和 SK-BR-3 用 Lapatinib (0.5-2 µM) 处理 48 h，使用 Western Blot 方法检测靶点蛋白表达水平。 结果：与较低浓度相比，用 1.0 μM Lapatinib 处理的 MDA-MB-231 和 SK-BR-3 细胞系中 PKM2 的表达均显著降低。[2] |
| 体内活性 | 方法：为检测体内抗肿瘤活性，将 Lapatinib (100 mg/kg) 腹腔注射给携带人胃癌肿瘤 N87 的 CD-1 athymic nude 小鼠，每天一次，持续三周。 结果：Lapatinib 导致 N87 异种移植物的肿瘤消退。[1] 方法：为检测体内抗肿瘤活性，将 Lapatinib (30-100 mg/kg，灌胃给药，每天两次持续二十一天) 和 Topoteca (6-10 mg/kg，腹腔注射，每四天一次持续三次) 灌胃给药给携带人乳腺癌肿瘤 BT474 的 SCID 小鼠。 结果：Lapatinib 和 Topoteca 组合在 ER2+BT474 异种移植物中显示出增强的功效。[3] |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 262.5 mg/mL (451.76 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9.3 mg/mL (16.01 mM), Solution. Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
| 关键字 | Lapatinib | Inhibitor | inhibit | HER2/ErbB2 | HER1 | GW-572016 | GW-2016 | GW2016 | GW 572016 | GW 2016 | GSK-572016 | GSK 572016 | Ferroptosis | ErbB-1 | Epidermal growth factor receptor | EGFR | Autophagy |
| 相关产品 | Guanidine hydrochloride | Naringin | Sodium Molybdate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Hemin | Hydroxychloroquine | Sildenafil citrate | Stavudine | Tamoxifen | Paeonol |
| 相关库 | Inhibitor Library | Bioactive Compound Library | Bioactive Compounds Library Max | Heat-Clearing and Detoxifying Traditional Chinese Medicine Compound Library | EMA Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Drug Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
官网有文献
相关实验
血浆治疗峰浓度Cmax； ② 避坑点：部分研究采用远超临床Cmax的给药浓度，体外数据临床转化价值极低； ③ 联合化疗配比两大方案： 4. 待检测药物分类 ① 标准化疗单药（临床一线/二线） 5-氟尿嘧啶(5-FU)、卡培他滨、奥沙利铂、顺铂、伊立替康、多西他赛、紫杉醇、表柔比星、多柔比星、卡铂 ② 临床标准联合化疗方案 FLOT、FOLFOX、FOLFIRI、ECF、5-FU+顺铂 ③ 靶向治疗药物 HER2抑制剂：曲妥珠单抗、木利替尼、拉帕替尼、阿法替尼、DS-8201； 激酶
技术资料暂无技术资料 索取技术资料
文献支持
拉帕替尼【231277-92-2】
￥173 - 1264
